Bristol-Myers Squibb (BMY) Tops Q1 EPS by 23c, Affirms EPS Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. SBUX
9. AXP
10. ZETA

Go back to Bristol-Myers Squibb (BMY) Tops Q1 EPS by 23c, Affirms EPS Guidance

Bristol Myers Squibb Reports Strong First Quarter 2020 Financial Results

May 7, 2020 6:59 AM EDT

Reports First Quarter Revenues of $10.8 Billion, an Increase of 82%; On a Pro Forma Basis, Revenue Increase of 13% or 8% Excluding Impact of COVID-19 Posts GAAP Loss Per Share of $0.34 and Non-GAAP EPS of $1.72 Achieves Multiple Significant Clinical and Regulatory Milestones Across Portfolio Adjusts 2020 GAAP EPS Guidance Range to $0.37-$0.57 and Affirms 2020 and 2021 Non-GAAP EPS Guidance Continues Progress on Integration Initiatives; $2.5B Synergy Target Remains on Track Contributes to Global COVID-19 Pandemic Response Through Research, Expansion of U.S. Patient Support Program and Support to... More